Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2014 | Original Article

Imaging of amyloid deposition in human brain using positron emission tomography and [¹⁸F]FACT: comparison with [¹¹C]PIB

Authors: Hiroshi Ito, Hitoshi Shinotoh, Hitoshi Shimada, Michie Miyoshi, Kazuhiko Yanai, Nobuyuki Okamura, Harumasa Takano, Hidehiko Takahashi, Ryosuke Arakawa, Fumitoshi Kodaka, Maiko Ono, Yoko Eguchi, Makoto Higuchi, Toshimitsu Fukumura, Tetsuya Suhara

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2014

Abstract

Purpose

The characteristic neuropathological changes in Alzheimer’s disease (AD) are deposition of amyloid senile plaques and neurofibrillary tangles. The ¹⁸F-labeled amyloid tracer, [¹⁸F]2-[(2-{(E)-2-[2-(dimethylamino)-1,3-thiazol-5-yl]vinyl}-1,3-benzoxazol-6-yl)oxy]-3-fluoropropan-1-ol (FACT), one of the benzoxazole derivatives, was recently developed. In the present study, deposition of amyloid senile plaques was measured by positron emission tomography (PET) with both [¹¹C]Pittsburgh compound B (PIB) and [¹⁸F]FACT in the same subjects, and the regional uptakes of both radiotracers were directly compared.

Methods

Two PET scans, one of each with [¹¹C]PIB and [¹⁸F]FACT, were performed sequentially on six normal control subjects, two mild cognitive impairment (MCI) patients, and six AD patients. The standardized uptake value ratio of brain regions to the cerebellum was calculated with partial volume correction using magnetic resonance (MR) images to remove the effects of white matter accumulation.

Results

No significant differences in the cerebral cortical uptake were observed between normal control subjects and AD patients in [¹⁸F]FACT studies without partial volume correction, while significant differences were observed in [¹¹C]PIB. After partial volume correction, the cerebral cortical uptake was significantly larger in AD patients than in normal control subjects for [¹⁸F]FACT studies as well as [¹¹C]PIB. Relatively lower uptakes of [¹¹C]PIB in distribution were observed in the medial side of the temporal cortex and in the occipital cortex as compared with [¹⁸F]FACT. Relatively higher uptake of [¹¹C]PIB in distribution was observed in the frontal and parietal cortices.

Conclusion

Since [¹⁸F]FACT might bind more preferentially to dense-cored amyloid deposition, regional differences in cerebral cortical uptake between [¹¹C]PIB and [¹⁸F]FACT might be due to differences in regional distribution between diffuse and dense-cored amyloid plaque shown in the autoradiographic and histochemical assays of postmortem AD brain sections.

Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–59.PubMedCrossRef

Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256:184–5.PubMedCrossRef

Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740–54.PubMedCrossRef

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19.PubMedCrossRef

Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci 2001;21:RC189.PubMed

Ono M, Wilson A, Nobrega J, Westaway D, Verhoeff P, Zhuang ZP, et al. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer’s disease. Nucl Med Biol 2003;30:565–71.PubMedCrossRef

Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer’s disease patients. J Nucl Med 2007;48:553–61.PubMedCrossRef

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129–35.PubMedCrossRef

Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 2009;50:1887–94.PubMedCentralPubMedCrossRef

10.

Nyberg S, Jönhagen ME, Cselényi Z, Halldin C, Julin P, Olsson H, et al. Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184. Eur J Nucl Med Mol Imaging 2009;36:1859–63.PubMedCentralPubMedCrossRef

11.

Cselényi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med 2012;53:415–24.PubMedCrossRef

12.

Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709–17.PubMedCrossRef

13.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006;129:2856–66.PubMedCrossRef

14.

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging β-amyloid burden in aging and dementia. Neurology 2007;68:1718–25.PubMedCrossRef

15.

Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer’s disease from normal and pathologic aging. Exp Neurol 1999;158:328–37.PubMedCrossRef

16.

Masliah E, Terry RD, Mallory M, Alford M, Hansen LA. Diffuse plaques do not accentuate synapse loss in Alzheimer’s disease. Am J Pathol 1990;137:1293–7.PubMedCentralPubMed

17.

Price JL. Diagnostic criteria for Alzheimer’s disease. Neurobiol Aging 1997;18:S67–70.PubMedCrossRef

18.

Furumoto S, Okamura N, Furukawa K, Tashiro M, Ishikawa Y, Sugi K, et al. A 18F-labeled BF-227 derivative as a potential radioligand for imaging dense amyloid plaques by positron emission tomography. Mol Imaging Biol 2013;15:497–506.PubMedCrossRef

19.

Shidahara M, Tashiro M, Okamura N, Furumoto S, Furukawa K, Watanuki S, et al. Evaluation of the biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe [18F]FACT in humans. EJNMMI Res 2013;3:32.PubMedCentralPubMedCrossRef

20.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.PubMedCrossRef

21.

Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–4.PubMedCrossRef

22.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.PubMedCrossRef

23.

Matsumoto K, Kitamura K, Mizuta T, Tanaka K, Yamamoto S, Sakamoto S, et al. Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high-sensitivity and high-resolution PET camera evaluated with the NEMA NU 2-2001 standard. J Nucl Med 2006;47:83–90.PubMed

24.

Ishikawa A, Kitamura K, Mizuta T, Tanaka K, Amano M, Inoue Y, et al. Implementation of on-the-fly scatter correction using dual energy window method in continuous 3D whole body PET scanning. IEEE Nucl Sci Symp Conf Rec 2005;5:2497–500.CrossRef

25.

Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528–47.PubMedCrossRef

26.

Ito H, Hietala J, Blomqvist G, Halldin C, Farde L. Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab 1998;18:941–50.PubMedCrossRef

27.

Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowiak RS. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 1990;10:458–66.PubMedCrossRef

28.

Ashburner J, Friston KJ. Voxel-based morphometry–the methods. Neuroimage 2000;11:805–21.PubMedCrossRef

29.

Müller-Gärtner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571–83.PubMedCrossRef

30.

Ito H, Inoue K, Goto R, Kinomura S, Taki Y, Okada K, et al. Database of normal human cerebral blood flow measured by SPECT: I. Comparison between I-123-IMP, Tc-99m-HMPAO, and Tc-99m-ECD as referred with O-15 labeled water PET and voxel-based morphometry. Ann Nucl Med 2006;20:131–8.PubMedCrossRef

31.

Higuchi M, Iwata N, Matsuba Y, Sato K, Sasamoto K, Saido TC. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 2005;8:527–33.PubMedCrossRef

32.

Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 2008;131:1630–45.PubMedCentralPubMedCrossRef

33.

Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Harigaya Y. Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol 1988;77:113–9.PubMed

34.

Jack Jr CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain 2008;131:665–80.PubMedCentralPubMedCrossRef

Title: Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB
Authors: Hiroshi Ito
Hitoshi Shinotoh
Hitoshi Shimada
Michie Miyoshi
Kazuhiko Yanai
Nobuyuki Okamura
Harumasa Takano
Hidehiko Takahashi
Ryosuke Arakawa
Fumitoshi Kodaka
Maiko Ono
Yoko Eguchi
Makoto Higuchi
Toshimitsu Fukumura
Tetsuya Suhara
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2620-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Imaging of amyloid deposition in human brain using positron emission tomography and [¹⁸F]FACT: comparison with [¹¹C]PIB

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2014

Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints

Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection

Molecular imaging of brown adipose tissue in health and disease

Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography

Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients

Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma